Development of a novel ovarian cancer molecular target therapy against cancer-related transcriptional factor, NAC1

Departments of Obstetrics and Gynecology Biocehmistory, Shimane University School of Medicine, Izumo, Japan.
Journal of Obstetrics and Gynaecology Research (Impact Factor: 0.93). 07/2012; 39(1). DOI: 10.1111/j.1447-0756.2012.01946.x
Source: PubMed
8 Reads
  • Source
    • "NAC1 inhibitors therefore may not only induce cell death but also suppress the metastasis of ovarian cancer cells. To this effect, we are presently researching agents that inhibit NAC1 [27]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian cancer is the most lethal gynecologic malignancy. Despite advances in chemotherapy, the five-year survival rate of advanced ovarian cancer patients with peritoneal metastasis remains around 30%. The most significant prognostic factor is stage, and most patients present at an advanced stage with peritoneal dissemination. There is often no clearly identifiable precursor lesion; therefore, the events leading to metastatic disease are poorly understood. This article reviews metastatic suppressor genes, the epithelial-mesenchymal transition (EMT), and the tumor microenvironment as they relate to ovarian cancer metastasis. Additionally, novel chemotherapeutic agents targeting the metastasis-related biochemical pathways are discussed.
    International Journal of Molecular Sciences 12/2012; 13(9):11705-17. DOI:10.3390/ijms130911705 · 2.86 Impact Factor